Kezar Life Sciences Inc
NASDAQ:KZR

Watchlist Manager
Kezar Life Sciences Inc Logo
Kezar Life Sciences Inc
NASDAQ:KZR
Watchlist
Price: 7.47 USD -0.93%
Market Cap: 54.5m USD
Have any thoughts about
Kezar Life Sciences Inc?
Write Note

Intrinsic Value

The intrinsic value of one KZR stock under the Base Case scenario is 10.73 USD. Compared to the current market price of 7.47 USD, Kezar Life Sciences Inc is Undervalued by 30%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

KZR Intrinsic Value
10.73 USD
Undervaluation 30%
Intrinsic Value
Price
Base Case Scenario

Valuation Backtest
Kezar Life Sciences Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for KZR cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about KZR?
Bearish
Neutral
Bullish
Discover Undervalued Stocks
Biotechnology Industry

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Kezar Life Sciences Inc

Provide an overview of the primary business activities
of Kezar Life Sciences Inc.

What unique competitive advantages
does Kezar Life Sciences Inc hold over its rivals?

What risks and challenges
does Kezar Life Sciences Inc face in the near future?

Summarize the latest earnings call
of Kezar Life Sciences Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Kezar Life Sciences Inc.

Provide P/S
for Kezar Life Sciences Inc.

Provide P/E
for Kezar Life Sciences Inc.

Provide P/OCF
for Kezar Life Sciences Inc.

Provide P/FCFE
for Kezar Life Sciences Inc.

Provide P/B
for Kezar Life Sciences Inc.

Provide EV/S
for Kezar Life Sciences Inc.

Provide EV/GP
for Kezar Life Sciences Inc.

Provide EV/EBITDA
for Kezar Life Sciences Inc.

Provide EV/EBIT
for Kezar Life Sciences Inc.

Provide EV/OCF
for Kezar Life Sciences Inc.

Provide EV/FCFF
for Kezar Life Sciences Inc.

Provide EV/IC
for Kezar Life Sciences Inc.

Show me price targets
for Kezar Life Sciences Inc made by professional analysts.

What are the Revenue projections
for Kezar Life Sciences Inc?

How accurate were the past Revenue estimates
for Kezar Life Sciences Inc?

What are the Net Income projections
for Kezar Life Sciences Inc?

How accurate were the past Net Income estimates
for Kezar Life Sciences Inc?

What are the EPS projections
for Kezar Life Sciences Inc?

How accurate were the past EPS estimates
for Kezar Life Sciences Inc?

What are the EBIT projections
for Kezar Life Sciences Inc?

How accurate were the past EBIT estimates
for Kezar Life Sciences Inc?

Compare the revenue forecasts
for Kezar Life Sciences Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Kezar Life Sciences Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Kezar Life Sciences Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Kezar Life Sciences Inc compared to its peers.

Compare the P/E ratios
of Kezar Life Sciences Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Kezar Life Sciences Inc with its peers.

Analyze the financial leverage
of Kezar Life Sciences Inc compared to its main competitors.

Show all profitability ratios
for Kezar Life Sciences Inc.

Provide ROE
for Kezar Life Sciences Inc.

Provide ROA
for Kezar Life Sciences Inc.

Provide ROIC
for Kezar Life Sciences Inc.

Provide ROCE
for Kezar Life Sciences Inc.

Provide Gross Margin
for Kezar Life Sciences Inc.

Provide Operating Margin
for Kezar Life Sciences Inc.

Provide Net Margin
for Kezar Life Sciences Inc.

Provide FCF Margin
for Kezar Life Sciences Inc.

Show all solvency ratios
for Kezar Life Sciences Inc.

Provide D/E Ratio
for Kezar Life Sciences Inc.

Provide D/A Ratio
for Kezar Life Sciences Inc.

Provide Interest Coverage Ratio
for Kezar Life Sciences Inc.

Provide Altman Z-Score Ratio
for Kezar Life Sciences Inc.

Provide Quick Ratio
for Kezar Life Sciences Inc.

Provide Current Ratio
for Kezar Life Sciences Inc.

Provide Cash Ratio
for Kezar Life Sciences Inc.

What is the historical Revenue growth
over the last 5 years for Kezar Life Sciences Inc?

What is the historical Net Income growth
over the last 5 years for Kezar Life Sciences Inc?

What is the current Free Cash Flow
of Kezar Life Sciences Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Kezar Life Sciences Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Kezar Life Sciences Inc

Current Assets 207m
Cash & Short-Term Investments 201.4m
Receivables 2.3m
Other Current Assets 3.3m
Non-Current Assets 14.3m
PP&E 8.7m
Other Non-Current Assets 5.6m
Current Liabilities 17.7m
Accounts Payable 8.3m
Accrued Liabilities 9.5m
Non-Current Liabilities 15.9m
Long-Term Debt 10.1m
Other Non-Current Liabilities 5.9m
Efficiency

Earnings Waterfall
Kezar Life Sciences Inc

Revenue
7m USD
Operating Expenses
-112.2m USD
Operating Income
-105.2m USD
Other Expenses
3.4m USD
Net Income
-101.9m USD

Free Cash Flow Analysis
Kezar Life Sciences Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

KZR Profitability Score
Profitability Due Diligence

Kezar Life Sciences Inc's profitability score is 17/100. The higher the profitability score, the more profitable the company is.

17/100
Profitability
Score

Kezar Life Sciences Inc's profitability score is 17/100. The higher the profitability score, the more profitable the company is.

KZR Solvency Score
Solvency Due Diligence

Kezar Life Sciences Inc's solvency score is 55/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Negative Net Debt
Low D/E
55/100
Solvency
Score

Kezar Life Sciences Inc's solvency score is 55/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

KZR Price Targets Summary
Kezar Life Sciences Inc

Wall Street analysts forecast KZR stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for KZR is 25.5 USD with a low forecast of 20.2 USD and a high forecast of 31.5 USD.

Lowest
Price Target
20.2 USD
170% Upside
Average
Price Target
25.5 USD
241% Upside
Highest
Price Target
31.5 USD
322% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for KZR?

Click here to dive deeper.

Dividends

Kezar Life Sciences Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for KZR is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Kezar Life Sciences Inc Logo
Kezar Life Sciences Inc

Country

United States of America

Industry

Biotechnology

Market Cap

55m USD

Dividend Yield

0%

Description

Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer in South San Francisco and California. The company is headquartered in South San Francisco, California and currently employs 56 full-time employees. The company went IPO on 2018-06-21. The firm's product portfolio includes KZR-616 and KZR-261. The KZR-616 is a selective immunoproteasome inhibitor that has completed Phase Ia testing in healthy volunteers and a Phase Ib trial in patients with systemic lupus erythematosus (SLE). KZR-261 is being studied in an open-label Phase I clinical trial designed to evaluate safety and tolerability, pharmacokinetics and pharmacodynamics, as well to explore preliminary anti-tumor activity. The firm has two drug development programs that harness different master regulators of cellular function, which include the immunoproteasome and the Sec61 translocon. The Company’s principal operations are in South San Francisco, California.

Contact

CALIFORNIA
South San Francisco
4000 Shoreline Ct Ste 300
+16508225600.0
kezarlifesciences.com

IPO

2018-06-21

Employees

56

Officers

Co-Founder, CEO & Director
Dr. Christopher J. Kirk Ph.D.
Co-Founder & Director
Mr. John Franklin Fowler
CFO & Secretary
Mr. Marc L. Belsky
Co-Founder
Dr. Jack Taunton Ph.D.
Senior Vice President of Investor Relations & External Affairs
Ms. Gitanjali Jain
Chief Legal Officer
Mr. Mark Schiller
Show More
Vice President of Human Resources
Mr. Joe Tedrick
Senior Vice President of Research & Drug Discovery
Dr. Neel K. Anand Ph.D.
Senior Vice President of Clinical Development
Mr. Zung To
Senior VP & Corporate Controller
Ms. Pattie Chiang
Show Less

See Also

Discover More
What is the Intrinsic Value of one KZR stock?

The intrinsic value of one KZR stock under the Base Case scenario is 10.73 USD.

Is KZR stock undervalued or overvalued?

Compared to the current market price of 7.47 USD, Kezar Life Sciences Inc is Undervalued by 30%.

Back to Top